AstraZeneca PLC press release (AZN): Q3 Non-GAAP EPS of $2.79. – Revenue of $16.21B (+6.7% Y/Y) beats by $210M. – FY2026 Guidance AstraZeneca reconfirms: Total Revenue is expected to increase by a mid-to-high single-digit percentage. – Core EPS is expected to increase
Astrazeneca PLC Non-gaap EPS of $2.79, Revenue of $16.21b Beats by $210m; Reaffirms Fy2026 Outlook
AstraZeneca PLC press release (AZN): Q3 Non-GAAP EPS of $2.79. - Revenue of $16.21B (+6.7% Y/Y) beats by $210M. - FY2026 Guidance AstraZeneca reconfirms: Total Revenue is expected to increase by a mid-to-high single-digit percentage. - Core EPS is expected to increase